Asked by: James Cartlidge (Conservative - South Suffolk)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, what assessment her Department has made of the potential impact of the designation of life sciences infrastructure on the life sciences sector.
Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
The designation of Life sciences as key national infrastructure will ensure that the Life Science sector can effectively operate in the UK, ensuring that the UK can maintain necessary health and resilience capabilities.
Asked by: Baroness Finlay of Llandaff (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking to ensure that patients with rare cancers are not without access to potentially life extending treatments while national appraisal and commissioning processes are ongoing.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government wants to ensure that all National Health Service patients, including patients with rare cancers, are able to benefit from rapid access to effective new medicines in a way that represents value to the taxpayer.
The National Institute for Health and Care Excellence (NICE) aims wherever possible to issue recommendations for the NHS on new medicines close to the time of licensing so that patients have rapid access to clinically and cost-effective medicines. The NHS is legally required to fund medicines recommended by NICE within three months of the publication of final guidance. NHS England funds NICE-recommended cancer medicines through the Cancer Drugs Fund from the point of positive draft NICE guidance, bringing forward patient access by approximately five months than would otherwise be the case.
The measures that we announced in the Life Sciences Sector Plan will further streamline the licensing and NICE appraisal processes reducing the time between marketing authorisation and national funding decisions.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of adjusting the National Institute for Health and Care Excellence cost-effectiveness thresholds for highly specialised technology in line with the new single technology appraisal cost-effectiveness thresholds due to come into effect from April.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
We have reached a landmark agreement with the United States of America that secures a preferential tariff rate of 0% for all pharmaceuticals exports to the US for at least three years, and preferential terms for the United Kingdom’s medical technology exports, meaning no additional new tariffs on medical technology. This means that, unlike anywhere else in the world, life sciences companies exporting medicines from the UK to the US will face no tariffs to do so, protecting jobs and investment in the UK.
The agreement will see the National Health Service invest approximately 25% more in innovative treatments which will be achieved through an increase to the standard cost-effectiveness threshold that the National Institute for Health and Care Excellence (NICE) uses and a change to the way in which NICE values health benefits to better reflect societal preferences.
There are currently no plans to increase the cost‑effectiveness threshold for the highly specialised technologies (HST) programme. The HST programme already operates at a much higher threshold than standard NICE technology appraisals, reflecting the challenges of bringing treatments for very rare conditions to market, and NICE has been able to recommend nearly all the treatments that have been evaluated through the HST programme for NHS use.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the impact of increasing the National Institute for Health and Care Excellence highly specialised technology cost-effectiveness threshold on patient access to rare disease medicines.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
We have reached a landmark agreement with the United States of America that secures a preferential tariff rate of 0% for all pharmaceuticals exports to the US for at least three years, and preferential terms for the United Kingdom’s medical technology exports, meaning no additional new tariffs on medical technology. This means that, unlike anywhere else in the world, life sciences companies exporting medicines from the UK to the US will face no tariffs to do so, protecting jobs and investment in the UK.
The agreement will see the National Health Service invest approximately 25% more in innovative treatments which will be achieved through an increase to the standard cost-effectiveness threshold that the National Institute for Health and Care Excellence (NICE) uses and a change to the way in which NICE values health benefits to better reflect societal preferences.
There are currently no plans to increase the cost‑effectiveness threshold for the highly specialised technologies (HST) programme. The HST programme already operates at a much higher threshold than standard NICE technology appraisals, reflecting the challenges of bringing treatments for very rare conditions to market, and NICE has been able to recommend nearly all the treatments that have been evaluated through the HST programme for NHS use.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what their rationale is for increasing the National Institute for Health and Care Excellence (NICE) cost-effectiveness thresholds for assessing new medicines to £25–30,000 per quality-adjusted life year; and whether they plan to apply the same proportionate increases to the NICE cost-effectiveness thresholds for highly specialised technologies.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
We have reached a landmark agreement with the United States of America that secures a preferential tariff rate of 0% for all pharmaceuticals exports to the US for at least three years, and preferential terms for the United Kingdom’s medical technology exports, meaning no additional new tariffs on medical technology. This means that, unlike anywhere else in the world, life sciences companies exporting medicines from the UK to the US will face no tariffs to do so, protecting jobs and investment in the UK.
The agreement will see the National Health Service invest approximately 25% more in innovative treatments which will be achieved through an increase to the standard cost-effectiveness threshold that the National Institute for Health and Care Excellence (NICE) uses and a change to the way in which NICE values health benefits to better reflect societal preferences.
There are currently no plans to increase the cost‑effectiveness threshold for the highly specialised technologies (HST) programme. The HST programme already operates at a much higher threshold than standard NICE technology appraisals, reflecting the challenges of bringing treatments for very rare conditions to market, and NICE has been able to recommend nearly all the treatments that have been evaluated through the HST programme for NHS use.
Asked by: Callum Anderson (Labour - Buckingham and Bletchley)
Question to the Department for Business and Trade:
To ask the Secretary of State for Business and Trade, what mechanisms exist within the UK-Indonesia Economic Growth Partnership to tackle regulatory divergence affecting cross-border trade and investment.
Answered by Chris Bryant - Minister of State (Department for Business and Trade)
The Economic Growth Partnership is a non-legally binding framework that will deepen cooperation between the UK and Indonesian Governments on areas of interest to our businesses. It is a signal of the UK and Indonesia’s commitment to grow our bilateral trade and investment.
The Economic Growth Partnership will address non-tariff and regulatory barriers raised by UK businesses, establish a regular dialogue to resolve issues and deepen co-operation in areas of commercial interest to the UK, including clean energy, health and life sciences, financial services and the digital economy.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential impact of NHS spending on pharmaceutical products on NHS service provision in the context of the UK-US trade deal.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
By increasing the standard National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold, we are increasing the value that we place on innovations that deliver improvements to patient health. Alongside the changes that we announced in the Life Sciences Sector Plan, this will increase both the speed and breadth of patient access to innovative medicines and encourage growth in United Kingdom-based clinical trials.
Costs will start smaller but will increase over time as the NICE approves more life improving and lifesaving medicines. Total costs over the Spending Review period are expected to be approximately £1 billion. But the final costs will depend on which medicines NICE decides to approve and the actual uptake of these.
This deal is a vital investment that builds on the strength of our National Health Service and world leading life sciences sector to increase access to life-changing medicines without taking essential funding from our frontline NHS services. We will always prioritise the needs of NHS patients and at the Spending Review we delivered a record real terms increase for day-to-day spending for the NHS in England up to April 2029.
This deal will be funded by allocations made at the Spending Review, where front line services will remain protected through the record funding secured. Future year funding will be settled at the next Spending Review.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent steps his Department is taking to improve research into (a) Ocular Melanoma and (b) other rare cancers.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests over £1.6 billion each year on research through the National Institute for Health and Care Research (NIHR) and in 2024/25 spent £141.6 million on cancer research, signalling its high priority.
One example of a recent investment into rare cancers is the NIHR’s investment of £13.7 million in December 2025 to support ground-breaking research to develop novel brain tumour treatments in the United Kingdom, with significant further funding announcements expected shortly. Research specifically on Ocular Melanoma includes a study completed in 2022 to develop AI Techniques to Predict Eye Cancer Using Big Longitudinal Data. The NIHR is committed to ensuring that all patients, including those with rare cancers, have access to cutting-edge clinical trials and innovative, lifesaving treatments, by working to fast-track clinical trials to drive global investment into life sciences, improve health outcomes, and accelerate the development of medicines and therapies of the future, including for rare cancers
The Government also supports the Rare Cancers Private Members Bill. The bill will make it easier for clinical trials on rare cancers to take place in England, by ensuring the patient population can be more easily contacted by researchers
The NIHR continues to welcome funding applications for research into less common cancers, including ocular cancer. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
Asked by: Seamus Logan (Scottish National Party - Aberdeenshire North and Moray East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will publish impact assessments, modelling and further detail on the UK-US pharmaceutical trade deal.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Tens of thousands of National Health Service patients will benefit from this deal, which will secure and expand access to vital drugs, and thereby safeguard our medicines supply chain.
Costs will start smaller but will increase over time as the National Institute for Health and Care Excellence (NICE) approves more life improving and lifesaving medicines. Total costs over the Spending Review period are expected to be approximately £1 billion. The final costs will depend on which medicines NICE recommends and the actual uptake of these.
This deal is a vital investment that builds on the strength of our NHS and world leading life sciences without taking essential funding from our frontline NHS services.
There are no current plans to publish an impact assessment or modelling on the United Kingdom and United States’ pharmaceutical trade deal. Further detail on the deal will be shared in due course.
Asked by: Ruth Jones (Labour - Newport West and Islwyn)
Question to the Home Office:
To ask the Secretary of State for the Home Department, what assessment she has made of the potential impact of The Public Order Act 2023 (Interference With Use or Operation of Key National Infrastructure) Regulations 2025 on the ability of (a) students and (b) academics to protest the use of animals in scientific research by universities.
Answered by Sarah Jones - Minister of State (Home Office)
On Thursday 27 November 2025, the Home Office laid an affirmative Statutory Instrument in Parliament to amend Section 7 and Section 8 of the Public Order Act 2023. This will amend the list of key national infrastructure within Section 7 of the Act, to add the Life Sciences sector and define the Life Sciences sector in Section 8 of the Act.
The definition of ‘Life Sciences sector’ for the purpose of this legislation to be added to Section 8 of the Act is: “infrastructure that primarily facilitates pharmaceutical research, or the development or manufacturing of pharmaceutical products; or which is used in connection to activities authorised under the Animals (Scientific Procedures) Act 1986”.
Under Section 7 of the Public Order Act 2023, a person commits an offence if:
The amendment is designed to address only certain behaviours impacting the Life Sciences sector. It does not ban protests. It specifically targets deliberate or reckless interference with infrastructure within the Life Sciences sector, that could undermine our sovereign capability to prepare for and respond to a pandemic.
Whether an activity meets the criminal threshold within Section 7 of the Public Order Act 2023 will be fact specific and is an operational matter for the police, the Crown Prosecution Service and the courts, who are all operationally independent from the government.